investigation of in-vitro antioxidant and neuroprotective effects of moringa oleifera root extract on sh-sy5y neuroblastoma cell line

Alzheimer’s disease (ad) is characterized by amyloid-beta (ab) plaques and neurofibrillary tangles, with acetylcholinesterase (ache) playing a crucial role in disease progression by breaking down acetylcholine (ach). inhibiting ache has emerged as a potential therapeutic strategy. this study aimed to assess the neuroprotective potential of methanolic and ethyl acetate extracts against beta amyloid-induced cytotoxicity in sh-sy5y cells. antioxidant properties were evaluated using dpph and frap assays, while inhibitory effects on ache and catalase enzymes were also examined. cytotoxicity studies on sh-sy5y cells indicated higher activity of the methanolic extract compared to the ethyl acetate extract. methanolic and ethyl acetate extracts demonstrated significant ache inhibitory activity with ic50 values of 95.21 µg/ml and 117.19 µg/ml, respectively, compared to tacrine. notably, beta amyloid exhibited significant cytotoxicity on sh-sy5y cells with an ic50 value of 20 µm/ml and cell viability of 44.44±1.27%. these findings underscore the potential of moringa oleifera root extracts as therapeutic agents for ad. both extracts demonstrated dose-dependent neuroprotective effects against beta amyloid-induced cytotoxicity. methanolic extract from moringa oleifera root showed superior antioxidant, ache inhibition, and anti-amyloidogenic properties compared to ethyl acetate extract. further research is needed to elucidate the molecular mechanisms underlying the observed anti-inflammatory effects at the cellular level. identification of bioactive compounds from these extracts holds promise for future therapeutic strategies against alzheimer’s disease.